Autologous lymphapheresis for the production of chimeric antigen receptor T cells.
Elizabeth S AllenDavid F StroncekJiaqiang RenAnne F EderKamille A WestTerry J FryDaniel W LeeCrystal L MackallCathy Conry-CantilenaPublished in: Transfusion (2017)
In most patients undergoing CAR T-cell therapy, leukapheresis is well tolerated, and adequate numbers of CD3+ lymphocytes are collected.